Cell Genesys (CEGE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SemiBull who wrote (1253)	9/2/2003 9:03:44 PM
From: SemiBull	Read Replies (1) of 1298

Cell Genesys Says Study Shows Positive Results for GVAX Tuesday September 2, 8:09 am ET SAN FRANCISCO (Dow Jones)--Cell Genesys Inc.'s Phase I melanoma cancer follow-up study demonstrated prolonged survival and increased time to disease progression in some patients using GVAX. In a press release Tuesday, the company said treatment with GVAX was safe and well tolerated in the outpatient setting. Ten of the 35 enrolled patients remain alive with a minimum follow-up of three years, including four patients without evidence of recurrent disease following surgical resection of their tumor. The vaccine was successfully manufactured in 97% of the enrolled patients and the side effect profile compares favorably to standard treatments, the company said. One complete response, one partial response and one mixed response were observed following the initial treatment period. The overall median survival was 15 months. Cell Genesys said the trial also demonstrated GVAX's ability to elicit a specific immune response directed against a patient's tumor. Seventeen of the 25 patients evaluated for enhanced antitumor immunity following treatment demonstrated induced immunologic reactivity against their tumors. Microscopic examination of surgically resected metastatic tumor showed an active immune response with T- and B-lymphocyte infiltration and tumor cell death in 10 of 16 cases. Lymphocytes stimulate compounds that hone in and kill tumor cells carrying a specific receptor. The study was conducted at Dana-Farber Cancer Institute, an affiliate of Harvard Medical School. The participants received patient-specific vaccine made directly from the participant's tumor biopsies. A majority of the patients had failed prior treatment including surgery, radiation, chemotherapy and interferon. Company Web site: cellgenesys.com -Eamon Beltran; Dow Jones Newswires; 201-938-5400

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next